Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Exploring Assura And Two Other Undervalued Small Caps With Insider Actions In The United Kingdom

In This Article:

In the United Kingdom, market sentiment is cautiously optimistic as investors digest the implications of recent political changes and economic indicators. With a new government in place and fewer businesses planning price increases, there may be subtle shifts in market dynamics that could highlight opportunities among undervalued small-cap stocks like Assura. Understanding what makes a good stock involves considering how well-positioned a company is to navigate current economic conditions, including its ability to adapt to political and economic shifts within the UK.

Top 10 Undervalued Small Caps With Insider Buying In The United Kingdom

Name

PE

PS

Discount to Fair Value

Value Rating

Ultimate Products

9.5x

0.7x

19.85%

★★★★★☆

Norcros

7.9x

0.5x

43.59%

★★★★★☆

THG

NA

0.4x

41.80%

★★★★★☆

CVS Group

21.0x

1.2x

41.78%

★★★★☆☆

M&C Saatchi

NA

0.5x

49.04%

★★★★☆☆

Bytes Technology Group

28.4x

6.4x

-12.42%

★★★☆☆☆

Robert Walters

20.3x

0.3x

38.84%

★★★☆☆☆

Trifast

NA

0.4x

-46.32%

★★★☆☆☆

GB Group

NA

3.3x

19.93%

★★★☆☆☆

Hochschild Mining

NA

1.8x

37.72%

★★★☆☆☆

Click here to see the full list of 33 stocks from our Undervalued Small Caps With Insider Buying screener.

Underneath we present a selection of stocks filtered out by our screen.

Assura

Simply Wall St Value Rating: ★★★☆☆☆

Overview: Assura is a healthcare real estate investment trust that focuses on the acquisition, development, and management of primary care facilities across the UK, with a market capitalization of approximately £1.74 billion.

Operations: The entity has demonstrated a consistently high gross profit margin, averaging approximately 92.4% over recent periods, with the latest figure at 90.81%. This reflects efficient cost management relative to its revenue generation, which stood at £157.8 million in the most recent reporting period.

PE: -43.8x

Assura, a specialist in healthcare property investment, recently showcased significant insider confidence with purchases made by executives. This move underscores a robust belief in the company's prospects amidst its strategic expansion into essential NHS infrastructure. With earnings forecasted to grow 40.91% annually and a notable reduction in net loss from GBP 119.2 million to GBP 28.8 million year-over-year, Assura's financial recovery appears well underway. The firm also announced a dividend increase and has entered into a GBP 250 million joint venture to enhance NHS community healthcare facilities, reflecting its commitment to long-term growth in this sector.